Extension usage examples:
Here's how our browser extension sees the article:
Article summary:
1. This article discusses the development of GALA- and CREKA-modified PEG-SS-PEI to deliver siRNAs targeting EGFR and BRD4 for TNBC therapy.
2. The complexes were characterized by dynamic light scattering (DLS) and transmission electron microscope (TEM).
3. The complexes significantly inhibited the proliferation, invasion and migration of MDA-MB-231 cells via the synergistic inhibition of EGFR/PI3K/Akt and BRD4/c-Myc pathways.
Article analysis:
The article “Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells” is a well written, comprehensive study that provides an in depth look at the potential use of GALA and CREKA modified PEG SS PEI to deliver siRNAs targeting EGFR and BRD4 for TNBC therapy. The article is well organized, clearly outlining the aims, materials and methods used, as well as providing detailed results from experiments conducted. The authors provide evidence to support their claims throughout the paper, including data from dynamic light scattering (DLS), transmission electron microscopy (TEM), Transwell invasion assay, wound healing assay, quantitative real time polymerase chain reaction (qRT PCR) and western blot analysis.
The article does not appear to be biased or one sided in its reporting; it presents both sides equally with no promotional content or partiality. It also notes possible risks associated with using this method of delivery for TNBC therapy such as toxicity towards normal cells due to chemotherapy treatment regimens. However, there are some missing points of consideration that could have been explored further such as potential side effects associated with using CPPs for delivery or other alternative methods that could be used for delivery instead of CPPs. Additionally, there is no discussion on how this method could be applied in a clinical setting or what further research needs to be done before it can be implemented clinically.
In conclusion, this article provides a comprehensive overview on the potential use of GALA and CREKA modified PEG SS PEI to deliver siRNAs targeting EGFR and BRD4 for TNBC therapy. It is well written with clear aims outlined at the beginning followed by detailed results from experiments conducted throughout the paper which provide evidence to support its claims. Although there are some missing points of consideration that could have been explored further such as potential side effects associated with using CPPs for delivery or other alternative methods that could be used for delivery instead of CPPs, overall this article appears to be trustworthy and reliable in its reporting without any bias or one sidedness present throughout its content.